483
Roslin Cell Therapies LimitedRoslin Cell Therapies Limited – FDA 483, Jan 21, 2025
Record Details
An FDA inspection of ROSLIN CELL THERAPIES LIMITED in Edinburgh revealed significant deficiencies across multiple areas. Observations included inadequate aseptic gowning during sterile drug product manufacturing, lack of access controls and audit trails for electronic production data, and failures within the quality control unit regarding deviation closure and training documentation. These issues indicate a lack of adherence to GMP requirements for sterile drug production and data integrity.
View Company Profile
ID · 0bf97933-396f-4abf-9880-4c5402d1c3b1
Other documents for Roslin Cell Therapies Limited
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.